UroGen Pharma Ltd.
UroGen Pharma Ltd.
Your view on URGN
Overview
What the company does, where it operates, and who runs it.
About UroGen Pharma Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Elizabeth A. Barrett
- Headquarters
- 400 Alexander Park, Princeton, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Elizabeth A. Barrett
- Headquarters
- 400 Alexander Park, Princeton, NJ, US
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.
It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer.
The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for UroGen Pharma Ltd., and the rating behind it. URGN last traded at $42.31; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for UroGen Pharma Ltd.. Starting points for UroGen Pharma Ltd.: EPS -$1.94, beta 1.58 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for UroGen Pharma Ltd.. UroGen Pharma Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for UroGen Pharma Ltd.. Trailing twelve-month EPS for UroGen Pharma Ltd. stands at -$1.94. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for UroGen Pharma Ltd.. UroGen Pharma Ltd. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
UroGen Pharma Ltd. valued side by side against its closest peers. UroGen Pharma Ltd. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold UroGen Pharma Ltd., and how their positions are changing. At a $2.06B market value, institutional positions materially move UroGen Pharma Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by UroGen Pharma Ltd. executives and directors. Shares of UroGen Pharma Ltd. have traded between $3.42 and $25.19 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming UroGen Pharma Ltd.. UroGen Pharma Ltd. is a $2.06B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming UroGen Pharma Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for UroGen Pharma Ltd.. Coverage tracks UroGen Pharma Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.